Chipps et al., 2017 - Google Patents
Asthma Yardstick: practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthmaChipps et al., 2017
View HTML- Document ID
- 17430649440240794454
- Author
- Chipps B
- Corren J
- Israel E
- Katial R
- Lang D
- Panettieri Jr R
- Peters S
- Farrar J
- Publication year
- Publication venue
- Annals of Allergy, Asthma & Immunology
External Links
Snippet
Current asthma guidelines recommend a control-based approach to management that involves assessment of impairment and risk followed by implementation of treatment strategies individualized according to the patient's needs and preferences. The fact that …
- 208000006673 Asthma 0 title abstract description 341
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chipps et al. | Asthma Yardstick: practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma | |
Corren et al. | Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma | |
Menzies-Gow et al. | The relationship of asthma biologics to remission for asthma | |
Khatri et al. | Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma | |
Anderson III et al. | New and future strategies to improve asthma control in children | |
Zervas et al. | An algorithmic approach for the treatment of severe uncontrolled asthma | |
Magnan et al. | Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment | |
Licari et al. | Omalizumab in children | |
Richeldi et al. | Macrolides for chronic asthma | |
Cockle et al. | Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison | |
US10577414B2 (en) | Use of reslizumab to treat moderate to severe eosinophilic asthma | |
Davies et al. | Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study | |
Domingo | Omalizumab for severe asthma: efficacy beyond the atopic patient? | |
Pavord et al. | Controversies in allergy: choosing a biologic for patients with severe asthma | |
Reibman et al. | Clinical and economic burden of severe asthma among US patients treated with biologic therapies | |
Hashimoto et al. | Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma–first initiators and switchers | |
Peters et al. | New and anticipated therapies for severe asthma | |
Ong | What’s new in the Global Initiative for Asthma 2018 report and beyond | |
Damask et al. | Targeted molecular therapies in allergy and rhinology | |
Nakamura et al. | Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: A post-marketing surveillance | |
Korn et al. | The German severe asthma patient: baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control | |
Cavaliere et al. | The spectrum of therapeutic activity of mepolizumab | |
Skolnik et al. | Primary care of asthma: new options for severe eosinophilic asthma | |
Geng et al. | Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma | |
Berger et al. | Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps |